{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-23-000004","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.349592+00:00","generated_at":"2026-06-20T18:44:32.600315+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Skye Bioscience extends credit agreement maturity to Feb 28, 2023 or sale of Verdélite Sciences","bullets":["Amendment No. 5 to Multi Draw Credit Agreement with Emerald Health Sciences extends maturity to earlier of sale of Verdélite Sciences, Feb 28, 2023, or termination date.","Director Bobby Rai appointed to Nominating and Corporate Governance Committee on January 5, 2023.","Credit agreement originally dated April 1, 2020, previously amended in March, September, and November 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-23-000004","json":"https://secwatch.observer/filing/0001516551-23-000004.json","markdown":"https://secwatch.observer/filing/0001516551-23-000004.md","text":"https://secwatch.observer/filing/0001516551-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000004/0001516551-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000004/skye-20221230.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:44:32.600315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"417e987910654bd11441ae702ad9a761d9cdab01","claim":"Skye Bioscience, Inc. amended Credit Agreement Amendment with Emerald Health Sciences, Inc. (effective 2022-12-30).","evidence_excerpt":"On December 30, 2022, Skye Bioscience, Inc. (the \"Company\") entered into Amendment No. 5 (the \"Credit Agreement Amendment\") to the Amended and Restated Multi Draw Credit Agreement (as amended, the \"Credit Agreement\") with Emerald Health Sciences, Inc. (\"Sciences\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000004/0001516551-23-000004-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Emerald Health Sciences, Inc."},{"label":"Effective","value":"2022-12-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}